Aydin Huseynov
Stock Analyst at Ladenburg Thalmann
(0.54)
# 3,787
Out of 4,814 analysts
58
Total ratings
24.49%
Success rate
-31.55%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Assumes: Buy | $11 | $4.81 | +128.69% | 1 | Mar 7, 2025 | |
| URGN UroGen Pharma | Assumes: Buy | $31 | $9.67 | +220.58% | 1 | Feb 19, 2025 | |
| MRKR Marker Therapeutics | Maintains: Buy | $11 → $19 | $1.16 | +1,537.93% | 2 | Oct 21, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $12 → $21 | $3.23 | +550.15% | 3 | Sep 16, 2024 | |
| CMPX Compass Therapeutics | Upgrades: Buy | $5 | $1.77 | +183.29% | 2 | Sep 16, 2024 | |
| ACRV Acrivon Therapeutics | Upgrades: Buy | $16 | $1.81 | +783.98% | 3 | Sep 16, 2024 | |
| CLDI Calidi Biotherapeutics | Initiates: Buy | $10 | $0.46 | +2,073.91% | 1 | Jun 27, 2024 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $24 → $25 | $11.25 | +122.22% | 2 | May 14, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Neutral | n/a | $0.12 | - | 3 | Mar 14, 2024 | |
| BDRX Biodexa Pharmaceuticals | Initiates: Buy | $200 | $1.43 | +13,886.01% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.00 | +600.00% | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.24 | +709.72% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $10.00 | +500.00% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $6 | $0.37 | +1,539.79% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $3.50 | +185.71% | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $375 → $240 | $0.72 | +33,279.69% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $182 | $7.28 | +2,400.00% | 2 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $180 → $80 | $0.27 | +29,518.66% | 1 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.91 | +588.47% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.34 | - | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.94 | - | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.03 | +485.37% | 1 | Jul 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $8.84 | +137.56% | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10,500 | $5.49 | +191,156.83% | 1 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $1.21 | +2,970.54% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $20 | $0.64 | +3,025.00% | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $563.16 | - | 6 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $89 | $58.22 | +52.87% | 2 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | n/a | $100.10 | - | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Speculative Buy | $1,000 | $0.69 | +145,460.41% | 1 | Jun 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $336 | $1.74 | +19,210.34% | 1 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.16 | +470.52% | 1 | Mar 19, 2020 |
Ardelyx
Mar 7, 2025
Assumes: Buy
Price Target: $11
Current: $4.81
Upside: +128.69%
UroGen Pharma
Feb 19, 2025
Assumes: Buy
Price Target: $31
Current: $9.67
Upside: +220.58%
Marker Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $11 → $19
Current: $1.16
Upside: +1,537.93%
Corvus Pharmaceuticals
Sep 16, 2024
Maintains: Buy
Price Target: $12 → $21
Current: $3.23
Upside: +550.15%
Compass Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $5
Current: $1.77
Upside: +183.29%
Acrivon Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $16
Current: $1.81
Upside: +783.98%
Calidi Biotherapeutics
Jun 27, 2024
Initiates: Buy
Price Target: $10
Current: $0.46
Upside: +2,073.91%
Capricor Therapeutics
May 14, 2024
Maintains: Buy
Price Target: $24 → $25
Current: $11.25
Upside: +122.22%
Spruce Biosciences
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.12
Upside: -
Biodexa Pharmaceuticals
Feb 8, 2024
Initiates: Buy
Price Target: $200
Current: $1.43
Upside: +13,886.01%
Dec 27, 2023
Initiates: Buy
Price Target: $7
Current: $1.00
Upside: +600.00%
Oct 10, 2023
Initiates: Buy
Price Target: $10
Current: $1.24
Upside: +709.72%
Sep 22, 2023
Initiates: Buy
Price Target: $60
Current: $10.00
Upside: +500.00%
Aug 14, 2023
Maintains: Buy
Price Target: $10 → $6
Current: $0.37
Upside: +1,539.79%
Jun 5, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $3.50
Upside: +185.71%
May 16, 2023
Maintains: Buy
Price Target: $375 → $240
Current: $0.72
Upside: +33,279.69%
Apr 28, 2023
Maintains: Buy
Price Target: $104 → $182
Current: $7.28
Upside: +2,400.00%
Apr 4, 2023
Maintains: Speculative Buy
Price Target: $180 → $80
Current: $0.27
Upside: +29,518.66%
Mar 7, 2023
Initiates: Buy
Price Target: $20
Current: $2.91
Upside: +588.47%
Nov 4, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.34
Upside: -
Aug 23, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.94
Upside: -
Jul 27, 2022
Initiates: Buy
Price Target: $6
Current: $1.03
Upside: +485.37%
Jul 13, 2022
Initiates: Buy
Price Target: $21
Current: $8.84
Upside: +137.56%
May 6, 2022
Initiates: Buy
Price Target: $10,500
Current: $5.49
Upside: +191,156.83%
May 2, 2022
Initiates: Buy
Price Target: $37
Current: $1.21
Upside: +2,970.54%
Nov 8, 2021
Upgrades: Buy
Price Target: $20
Current: $0.64
Upside: +3,025.00%
Nov 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $563.16
Upside: -
Jul 20, 2021
Upgrades: Buy
Price Target: $89
Current: $58.22
Upside: +52.87%
Sep 30, 2020
Initiates: Hold
Price Target: n/a
Current: $100.10
Upside: -
Jun 16, 2020
Initiates: Speculative Buy
Price Target: $1,000
Current: $0.69
Upside: +145,460.41%
May 21, 2020
Initiates: Buy
Price Target: $336
Current: $1.74
Upside: +19,210.34%
Mar 19, 2020
Initiates: Buy
Price Target: $18
Current: $3.16
Upside: +470.52%